Aptose Bio out-licenses APL-581 for up to $125M; shares up 13% premarket [Seeking Alpha]
Aptose Biosciences, Inc. - Common Shares (APTO)
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aptose.com/investors
Company Research
Source: Seeking Alpha
Aptose Bio out-licenses APL-581 for up to $125M; shares up 13% premarketNano cap Aptose Biosciences (NASDAQ:APTO) is up 13% premarket on light volume in response to itsannouncement that it has inked an exclusive global license agreement with OHM Oncology granting it development, manufacturing and commercialization rights to APL-581 and certain other molecules from Aptose's dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.Aptose retains reacquisition rights to certain molecules while OHM has the rights to develop and sublicense all other molecules.Under the terms of the agreement, Aptose will receive a nominal upfront cash payment, up to $125M in milestones and royalties on net sales of commercialized products.See all stocks on the move »Now read:Titan Medical readies equity offering »
Show less
Read more
Impact Snapshot
Event Time:
APTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APTO alerts
High impacting Aptose Biosciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
APTO
News
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 [Yahoo! Finance]Yahoo! Finance
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024GlobeNewswire
- Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.MarketBeat
- Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
APTO
Earnings
- 11/9/23 - Beat
APTO
Analyst Actions
- 3/27/24 - HC Wainwright
APTO
Sec Filings
- 5/10/24 - Form 4
- 5/6/24 - Form 8-K
- 5/1/24 - Form 8-K
- APTO's page on the SEC website